Stocktoria
JOHNSON & JOHNSON JNJ
JOHNSON & JOHNSON (JNJ) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $94.2B at a 28.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.24 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | Guggenheim | Buy (main) |
| 2026-08-03 | Wells Fargo | Overweight (main) |
| 2026-07-17 | Guggenheim | Buy (reit) |
| 2026-07-16 | Raymond James | Outperform (main) |
| 2026-07-16 | RBC Capital | Outperform (reit) |
| 2026-07-16 | Wells Fargo | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
| ABT | ABBOTT LABORATORIES | 5/9 | 4.85 | 25.1 | +5.7% |
About JOHNSON & JOHNSON
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
FAQ
Is JNJ financially healthy?
JOHNSON & JOHNSON's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does JNJ pay a dividend?
No, JOHNSON & JOHNSON does not currently pay a dividend.
How profitable is JNJ?
In FY2025, JOHNSON & JOHNSON had a net margin of 28.5% and a return on equity of 32.9%.
Is JNJ overvalued or undervalued?
JOHNSON & JOHNSON trades at about 23.7× trailing earnings — near its 10-year norm (10-year range 11.6×–294.0×, median 24.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for JNJ?
The average Wall-Street price target for JOHNSON & JOHNSON is $272.50, about 4.5% above the recent price, from 22 analysts (consensus: buy).
Is JNJ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on JOHNSON & JOHNSON: a Piotroski F-score of 4/9, a P/E of about 22.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.